Navacaprant

Navacaprant
Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140; NMRA-335140
Routes of; administration	Oral
Drug class	κ-Opioid receptor antagonist
Identifiers
	IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine;
CAS Number	2244614-14-8;
PubChem CID	137434175;
ChemSpider	78316413;
UNII	XK5ILZ28KI;
KEGG	D12869;
CompTox Dashboard (EPA)	DTXSID401104655 ;
ECHA InfoCard	100.513.362
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C;
	InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3; Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N;

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression.^[2]^[1]^[3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.^[1] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.^[1]^[4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.^[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.^[5]

References

1 2 3 4 "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
↑ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
↑ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
↑ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
1 2 Taylor, Nick Paul (2 January 2025). "Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%". Fierce Biotech. Retrieved 7 March 2025.

External links

BTRX 335140 - AdisInsight

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 3 4 "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.

[BlackThornRx-2] "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.

[pmid30707578-3] Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.

[4] Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.

[Taylor2025-5] 1 2 Taylor, Nick Paul (2 January 2025). "Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%". Fierce Biotech. Retrieved 7 March 2025.

[1]

[2]

[3]

[4]

[5]

This page was redesigned at the edge.

Navacaprant

See also

References

External links